STAREE Trial Shows Statins Reduce Cardiovascular Events in Healthy Seniors
The STAREE trial randomized healthy adults aged 70 and older to daily atorvastatin 40 mg or placebo and found a significant reduction in the composite of cardiovascular death, nonfatal MI or stroke, or coronary revascularization over 6 years. The benefit was consistent across subgroups, though disability-free survival was not improved. The results support the use of statins for primary prevention in this age group.
The trial enrolled nearly 10,000 relatively healthy adults aged 70 and older, with participants initially receiving a 20-mg dose before uptitration to 40 mg as tolerated. The pragmatic design allowed for substantial crossover and adherence variability, which investigators noted likely made their benefit estimates conservative.
Safety data showed comparable overall serious adverse event rates between groups at 2.7%. However, small imbalances emerged in musculoskeletal or connective tissue events, hepatobiliary events, and diabetes-related events among atorvastatin recipients. The findings were published simultaneously in the New England Journal of Medicine and presented at the ESC meeting in Munich.
This trial may shift clinical practice for primary prevention in older adults, potentially prompting updated guidelines to strengthen recommendations beyond the current weak class IIb designation. Millions of healthy seniors could face new conversations with physicians about statin initiation, weighing modest cardiovascular benefits against small risks of muscle, liver, and metabolic side effects. The disability-free survival null result may temper enthusiasm, suggesting statins extend cardiovascular health without necessarily preserving overall independence in later life.